- Home
- EIC vs NKTR Comparison
EIC vs NKTR Comparison
Compare EIC & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- NKTR
- Stock Information
- Founded
- EIC N/A
- NKTR 1990
- Country
- EIC United States
- NKTR United States
- Employees
- EIC N/A
- NKTR N/A
- Industry
- EIC Finance/Investors Services
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- NKTR Health Care
- Exchange
- EIC Nasdaq
- NKTR Nasdaq
- Market Cap
- EIC 242.6M
- NKTR 238.7M
- IPO Year
- EIC 2019
- NKTR 1994
- Fundamental
- Price
- EIC $16.42
- NKTR $1.32
- Analyst Decision
- EIC
- NKTR Buy
- Analyst Count
- EIC 0
- NKTR 4
- Target Price
- EIC N/A
- NKTR $2.50
- AVG Volume (30 Days)
- EIC 116.0K
- NKTR 988.9K
- Earning Date
- EIC 11-14-2023
- NKTR 11-05-2024
- Dividend Yield
- EIC 13.63%
- NKTR N/A
- EPS Growth
- EIC N/A
- NKTR N/A
- EPS
- EIC 0.80
- NKTR N/A
- Revenue
- EIC N/A
- NKTR $93,157,000.00
- Revenue This Year
- EIC N/A
- NKTR N/A
- Revenue Next Year
- EIC N/A
- NKTR N/A
- P/E Ratio
- EIC $20.31
- NKTR N/A
- Revenue Growth
- EIC N/A
- NKTR 6.17
- 52 Week Low
- EIC $13.00
- NKTR $0.41
- 52 Week High
- EIC $16.48
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- EIC 73.63
- NKTR 56.07
- Support Level
- EIC $15.83
- NKTR $1.11
- Resistance Level
- EIC $15.97
- NKTR $1.39
- Average True Range (ATR)
- EIC 0.18
- NKTR 0.09
- MACD
- EIC 0.07
- NKTR 0.01
- Stochastic Oscillator
- EIC 98.11
- NKTR 75.00
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.